Transdermal therapeutic systems (TTSs) are commonly used to treat many diverse medical conditions. There are several advantages to this form of drug delivery; however, adverse cutaneous reactions are common. This review article provides an update on skin reactions due to TTSs containing medications newly available in TTS form, including buprenorphine, diclofenac, lidocaine, oxybutynin, rotigotine, methylphenidate, rivastigmine, teriparatide, and nicardipine.
Perez-PerezL, CabanillasM, LoureiroM, et al.Allergic contact dermatitis due to transdermal buprenorphine. Contact Dermatitis, 2008; 58:310-2.
3.
WuJ, PaudelKS, StrasingerC, et al.Programmable transdermal drug delivery of nicotine using carbon nanotube membranes. Proc Natl Acad Sci U S A, 2010; 107:11698-702.
4.
CosmanF, LaneNE, BologneseMA, et al.Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab, 2010; 95:151-8.
5.
AleI, LachapelleJ, MaibachH. Skin tolerability associated with transdermal drug delivery systems: an overview. Adv Ther, 2009; 26: 920-35.
6.
HoldinessMR. A review of contact dermatitis associated with transdermal therapeutic systems. Contact Dermatitis, 1989; 20:3-9.
7.
WarshawEM, PallerAS, FowlerJF, ZirwasMJ. Practical management of cutaneous reactions to the methylphenidate patch: recommendations from a Dermatology Expert Panel Consensus Meeting. Clin Ther, 2008; 30:326-37.
8.
HoganDJ, MaibachHI. Adverse dermatologie reactions to transdermal drug delivery systems. J Am Acad Dermatol, 1990; 22(5 Pt 1):811-4.
9.
MaibachHI. Oral substitution in patients sensitized by transdermal clonidine treatment. Contact Dermatitis, 1987; 16:1-8.
Vander HulstK, Parera AmerE, JacobsC, et al.Allergic contact dermatitis from transdermal buprenorphine. Contact Dermatitis, 2008; 59:366-9.
17.
Schmid-GrendelmeierP, PokornyR, GasserU, RicharzU. A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers. Curr Med Res Opin, 2006; 22:501-9.
18.
BohmeK. Buprenorphine in a transdermal therapeutic system—a new option. Clin Rheumatol, 2002; 21,Suppl 1:S13-6.
19.
GriessingerN, SittlR, LikarR. Transdermal buprenorphine in clinical practice—a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin, 2005; 21:1147-56.
20.
StutiusLM, PessachI, LeeJ, et al.Sublingual desensitization for buprenorphine hypersensitivity. J Allergy Clin Immunol, 2010; 125: 938-9.
21.
A diclofenac patch (Flector) for pain: Med Lett Drugs Ther. 2008; 50:1-2.
22.
HsiehLF, HongCZ, ChernSH, ChenCC. Efficacy and side effects of diclofenac patch in treatment of patients with myofascial pain syndrome of the upper trapezius. J Pain Symptom Manage, 2010; 39: 116-25.
23.
PetersenB, RovatiS. Diclofenac epolamine (Flector) patch: evidence for topical activity. Clin Drug Investig, 2009; 29:1-9.
GammaitoniAR, AlvarezNA, GalerBS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol, 2003; 43:111-7.
30.
WilhelmIR, TzabazisA, LikarR, et al.Long-term treatment of neuropathic pain with a 5% lidocaine medicated plaster. Eur J Anaesthesiol, 2010; 27:169-73.
31.
ArgoffCE, GalerBS, JensenMP, et al.Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale. Curr Med Res Opin, 2004; 20Suppl 2:S21-8.
32.
GammaitoniAR, DavisMW. Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother, 2002; 36:236-40.
33.
GalerBS, RowbothamMC, PeranderJ, FriedmanE. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain, 1999; 80:533-8.
34.
RowbothamMC, DaviesPS, VerkempinckC, GalerBS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain, 1996; 65:39-44.
WarshawEM, SchramSE, BelsitoDV, et al.Patch-test reactions to topical anesthetics: retrospective analysis of cross-sectional data, 2001 to 2004. Dermatitis, 2008; 19:81-5.
37.
DmochowskiRR, StarkmanJS, DavilaGW. Transdermal drug delivery treatment for overactive bladder. Int Braz J Urol, 2006; 32: 513-20.
38.
DmochowskiRR, SandPK, ZinnerNR, et al.Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology, 2003; 62:237-42.
39.
MacdiarmidSA. The evolution of transdermal/topical overactive bladder therapy and its benefits over oral therapy. Rev Obstet Gynecol, 2009; 2:116-21.
40.
SandP, ZinnerN, NewmanD, et al.Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int, 2007; 99:836-44.
41.
ChenJJ, SwopeDM, DashtipourK, LyonsKE. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson’s disease. Pharmacotherapy, 2009; 29: 1452-67.
42.
GonzalezMA, CampbellD, RubinJ. Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 2009; 19:227-32.
43.
WarshawEM, SquiresL, LiY, et al.Methylphenidate transdermal system: a multisite, open-label study of dermal reactions in pediatric patients diagnosed with ADHD. Prim Care Companion J Clin Psychiatry, 2010; 12:E1-E9.
44.
KurzA, FarlowM, LefevreG. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review. Int J Clin Pract, 2009; 63:799-805.
45.
WinbladB, MachadoJC. Use of rivastigmine transdermal patch in the treatment of Alzheimer’s disease. Expert Opin Drug Deliv, 2008; 5:1377-86.
46.
WinbladB, CummingsJ, AndreasenN, et al.A six-month doubleblind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease—rivastigmine patch versus capsule. Int J Geriatr Psychiatry, 2007; 22:456-67.
47.
CummingsJL, FarlowMR, MengX, et al.Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer’s disease. Clin Drug Investig, 2010; 30:41-9.
48.
LefevreG, SedekG, HuangHL, et al.Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol, 2007; 47:471-8.
49.
KrishnaiahYS, SatyanarayanaV, BhaskarP. Formulation and in vivo evaluation of membrane-moderated transdermal therapeutic systems of nicardipine hydrochloride using carvone as a penetration enhancer. Drug Deliv, 2003; 10:101-9.
50.
MutalikS, UdupaN, KumarS, et al.Glipizide matrix transdermal systems for diabetes mellitus: preparation, in vitro and preclinical studies. Life Sci, 2006; 79:1568-77.
